Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
Leuk Res. 2011 Jan;35(1):14-21. doi: 10.1016/j.leukres.2010.07.030. Epub 2010 Aug 16.
Allogeneic hematopoietic stem cell transplantation (HSCT) for leukemia can play a major role in reducing the risk of relapse by inducing a graft versus leukemia (GVL) effect. Here, we review the effectiveness of mismatching inhibitory killer-cell-immunoglobulin-like receptors (KIR) on donor natural killer (NK) cells as a mechanism for GVL. We review the range of KIR and the importance of T cell and NK cell content of the graft, together with considerations of the graft source. Further understanding of conditioning and mechanisms to reduce graft versus host disease (GVHD) will improve our ability to manipulate NK cells in HSCT.
同种异体造血干细胞移植（HSCT）可通过诱导移植物抗白血病（GVL）效应来降低白血病复发的风险。在此，我们回顾了供体自然杀伤（NK）细胞中抑制性杀伤细胞免疫球蛋白样受体（KIR）错配作为 GVL 机制的有效性。我们回顾了 KIR 的范围以及移植物中 T 细胞和 NK 细胞含量的重要性，同时考虑了移植物来源。进一步了解调理和减少移植物抗宿主病（GVHD）的机制将提高我们在 HSCT 中操纵 NK 细胞的能力。
